Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 416 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control cream Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)

NCT03372811
View directory record Official record
Conditions
Psoriasis Vulgaris, Topical Administration
Interventions
Total coumarin (TC) cream, Vehicle
Drug
Lead sponsor
Psoriasis Research Institute of Guangzhou
Industry
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 24, 2026, 5:34 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris

NCT03361345
View directory record Official record
Conditions
Postinflammatory Hyperpigmentation
Interventions
Tranexamic Acid, Vehicle
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Assess the Effectiveness of Use of Three Experimental Denture Adhesives Compared to Using No-Adhesive

NCT07496164
View directory record Official record
Conditions
Denture Retention
Interventions
Experimental Denture Adhesive 1, Experimental Denture Adhesive 2, Experimental Denture Adhesive 3, Poligrip Power Hold + Seal
Device
Lead sponsor
HALEON
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses

NCT00608634
View directory record Official record
Conditions
Precancerous Condition
Interventions
perillyl alcohol, placebo
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 4 Interventional Results available

Pain Control in Pediatric Oncology: Utility of EMLA Cream vs Lidocaine Injection in Lumbar Punctures

NCT04003012
View directory record Official record
Conditions
Leukemia-Lymphoma
Interventions
EMLA, Lidocaine
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

NCT04773587
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Roflumilast Cream 0.15%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
42
States / cities
Montgomery, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Peanuts and Peanut Products on Glucose Control and Vascular Function

NCT01405300
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Control, Peanut
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
20 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

NCT01068158
View directory record Official record
Conditions
Head Lice
Interventions
0.5% Ivermectin Cream, Placebo control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
5 Months and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
7
States / cities
Little Rock, Arkansas • Delray Beach, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Not applicable Interventional

The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea

NCT03392558
View directory record Official record
Conditions
Rosacea
Interventions
Burt's Bees Skin Care Regimen, Control Regimen
Other
Lead sponsor
Burt's Bees Inc.
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 24, 2026, 5:34 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Ice Versus EMLA for Pain in Laser Hair Removal

NCT02318654
View directory record Official record
Conditions
Hair Removal
Interventions
Ice Pack, Topical EMLA cream
Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Not applicable Interventional

Clinical Trial to Assess the Effects of Topical Lotions on Changes in the Skin Microbiome and Associations With Itch

NCT03673059
View directory record Official record
Conditions
Microbiota
Interventions
OTC Eczema Moisturizer Regimen, Cosmetic Moisturizer Regimen
Drug · Other
Lead sponsor
Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.
Industry
Eligibility
16 Years to 50 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Colorado Springs, Colorado • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunologic Profile of Chronically Photodamaged Skin

NCT02889159
View directory record Official record
Conditions
Photoaged Skin, Normal Skin
Interventions
Candida albicans antigen, histamine phosphate, imiquimod 5% cream, Tape Stripping
Biological · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

NCT03445650
View directory record Official record
Conditions
Sjogren-Larsson Syndrome
Interventions
ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT02228850
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Alprostadil, Placebo
Drug · Other
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Industry
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neuromodulation of Lidocaine and Capsaicin Cream Effects on Pain Experience

NCT03102710
View directory record Official record
Conditions
Pain
Interventions
transcranial direct current stimulation (tDCS), Lidocaine cream, Capsaicin cream, Control cream
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

NCT00838708
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
SRD174 Cream, vehicle cream
Drug · Other
Lead sponsor
Serentis Ltd.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Oceanside, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2009 · Synced Oct 24, 2026, 5:34 PM EDT
Withdrawn Not applicable Interventional

Randomized CO2 vs Sham Laser Treatment of Provoked Vestibulodynia

NCT03390049
View directory record Official record
Conditions
Vestibulodynia
Interventions
Fractional CO2 Laser Treatment, Sham Laser Treatment
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

NCT03571620
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Q301 Cream, Vehicle
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
12 Years to 70 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

NCT02210689
View directory record Official record
Conditions
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
Interventions
clindamycin phosphate vaginal cream 2%, placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 24, 2026, 5:34 PM EDT
Not yet recruiting Phase 2 Interventional

Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains

NCT07436611
View directory record Official record
Conditions
Port Wine Stains
Interventions
Rapamycin cream, Pulsed dyed laser
Drug · Procedure
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
Up to 10 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

NCT05332366
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 24, 2026, 5:34 PM EDT
Recruiting Phase 2 Interventional

HPV Vaccine, Imiquimod, and Metformin Combination Trial

NCT06686043
View directory record Official record
Conditions
Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma
Interventions
HPV vaccine, Imiquimod, and metformin combination therapy
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 24, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation

NCT01066585
View directory record Official record
Conditions
Head Lice
Interventions
Ivermectin Cream, vehicle control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
6 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Yuma, Arizona • Dinuba, California • Plantation, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 24, 2026, 5:34 PM EDT